Study on Remogliflozin, Vildagliptin, and Metformin for Type 2 Diabetes
Author Information
Author(s): Agarwal Prabhat K, Bhushan Divendu, Bhate Amit, Naik Sunil, Adwani Shailesh, Kushwaha J S, Bhushan Sumit, Mane Abhishek, Gadkari Rujuta, Choudhari Sanjay, Patil Saiprasad, Barkate Hanmant
Hypothesis
The study aims to evaluate the safety and efficacy of a fixed dose combination of Remogliflozin, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus.
Conclusion
The triple combination of RMV was found to be safe and effective in improving glycemic control in patients with Type 2 Diabetes Mellitus who were uncontrolled on dual therapy.
Supporting Evidence
- 45.1% of patients achieved target HbA1c levels of ≤7% at week 24.
- Significant reductions in fasting plasma glucose and postprandial glucose levels were observed.
- Renal parameters remained stable or improved throughout the study.
- No serious adverse events were recorded during the study.
Takeaway
This study shows that a new combination of diabetes medications can help people with high blood sugar feel better and stay healthy.
Methodology
A prospective, multicentre, baseline controlled, single arm, interventional study was conducted with 215 patients to assess the safety and efficacy of the drug combination over 24 weeks.
Potential Biases
Potential confounders like changes in lifestyle or concurrent medications could impact the outcomes.
Limitations
The study had a single-arm design, short follow-up duration, and excluded patients with certain comorbidities.
Participant Demographics
Mean age of participants was 46.4 years, with 64% male and 36% female.
Statistical Information
P-Value
p<0.00001
Statistical Significance
p<0.00001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website